Ginkgo Bioworks Holdings (DNA) agreed to provide data-generation services to Lilly TuneLab, an AI-driven drug-discovery platform created by Eli Lilly (LLY).
Ginkgo Datapoints will provide discovery data, including small molecule developability and antibody developability testing, to companies participating in TuneLab.
"For TuneLab's biotech partners, this means access to state-of-the-art lab automation capable of running experiments without manual bottlenecks," Ginkgo Bioworks said Wednesday in a statement.
Financial terms weren't disclosed.
Ginkgo shares rose 2.3% in Wednesday trading, and Lilly gained 0.7%.
Price: $7.15, Change: $+0.16, Percent Change: +2.29%